S&P Futures
4,569.25 +6.25 (+0.14%) Dow Futures
35,498.00 +53.00 (+0.15%) Nasdaq Futures
16,070.50 +22.50 (+0.14%) Russell 2000 Futures
1,802.00 +5.00 (+0.28%) Crude Oil
76.52 +0.11 (+0.14%) Gold
2,045.00 +5.00 (+0.25%)
Cyclacel Pharmaceuticals, Inc. (CYCC)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.2890 |
| Open | 0.3100 |
| Bid | 0.2920 x 1400 |
| Ask | 0.3499 x 900 |
| Day's Range | 0.2807 - 0.3130 |
| 52 Week Range | 0.2700 - 1.1700 |
| Volume | |
| Avg. Volume | 133,829 |
| Market Cap | 3.77M |
| Beta (5Y Monthly) | 1.06 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.9400 |
| Earnings Date | Nov 13, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 13.67 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CYCC
Related Research
- Cyclacel Pharmaceuticals, Inc.The Argus ESG Model PortfolioSustainable Impact Investing, or ESG investing, is gaining traction not only with Argus Research clients but also with the global investment community. BlackRock CEO Lawrence Fink, who oversees approximately $9 trillion in assets, announced in January 2020 that his firm would be investing in companies that are making progress on sustainability. He doubled down in his January 2021 letter, calling on company managements to disclose their plans for making their businesses "compatible with a net-zero economy" by 2050. As assets have flowed in over the past 40 years, Sustainable Impact Investing has evolved. The discipline, originally known as Socially Responsible Investing, focused at first on excluding companies that conducted business in South Africa, or participated in industries such as tobacco, alcohol, and firearms. Performance of these initial strategies lagged, and the approach has been modified. Now, instead of merely identifying industries to avoid, the discipline promotes "sustainable" business practices across all industries that can have an "impact" on global issues such as climate, hunger, poverty, disease, shelter, and workers' rights.RatingFair ValueEconomic Moat9 hours agoArgus Research
GlobeNewswireCyclacel Receives Notification of Deficiency From Nasdaq Regarding Timely Filing of Quarterly Report on Form 10-Q
BERKELEY HEIGHTS, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced that it received a notice of non-compliance from Nasdaq Stock Market LLC (“Nasdaq”) on November 21, 2023 stating that, as a result of not having timely filed its quarterly report on Form 10-Q for the quarter ended September 30, 2023, the Company
Insider MonkeyCyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript
Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Q3 2023 Earnings Call Transcript November 13, 2023 Operator: Good afternoon, and welcome to the Cyclacel Pharmaceuticals Third Quarter 2023 Results Conference Call and Webcast. [Operator Instructions] Please note, today’s call is being recorded. I would now like to turn the conference call over to the company. Please go ahead. Grace […]
- GlobeNewswire
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update
- Cyclacel Expects to Release Updated Phase 1/2 Clinical and Biomarker Data with Oral Fadraciclib and Provide Safety, Efficacy and Putative Mechanism Update for Oral Plogosertib - - Management to Host Conference Call at 4:30 pm ET Today - BERKELEY HEIGHTS, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer cell biology, announced today third
